News
-
-
-
PRESS RELEASE
Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers -
-
PRESS RELEASE
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 results for obefazimod in ulcerative colitis trials, meeting key endpoints and demonstrating favorable tolerability. Conference call scheduled for more insights -
-
-
-
PRESS RELEASE
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax announced the results of its June 6, 2025 Annual General Meeting. Shareholders adopted all proposed resolutions including financial statements and appointments. More details on the vote results available on the Company's website -
